COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01184599
Recruitment Status : Unknown
Verified May 2010 by Kagawa University.
Recruitment status was:  Recruiting
First Posted : August 19, 2010
Last Update Posted : June 27, 2011
Information provided by:
Kagawa University

Brief Summary:
The purpose of this study is to evaluate the effect of aliskiren, a novel direct rennin inhibitor, on renal function and progress of renal disease in hypertensive patients with IgA nephropathy.

Condition or disease Intervention/treatment Phase
Glomerulonephritis, IGA Hypertension Drug: aliskiren Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : June 2010
Estimated Primary Completion Date : March 2013

Resource links provided by the National Library of Medicine

Drug Information available for: Aliskiren

Intervention Details:
  • Drug: aliskiren
    150 mg/day p.o.

Primary Outcome Measures :
  1. Renal function (Creatinine clearance) [ Time Frame: One year (every 6 months) ]
  2. Urinary protein [ Time Frame: One year (every 6 months) ]

Secondary Outcome Measures :
  1. Urinary angiotensinogen [ Time Frame: One year (every 6 months) ]
  2. Urinary type 4 collagen [ Time Frame: One year (every 6 months) ]
  3. Urinary Transforming growth factor-beta [ Time Frame: One year (every 6 months) ]
  4. High-sensitivity C-reactive protein [ Time Frame: One year (every 6 months) ]
  5. Plasma Rennin Activity [ Time Frame: One year (every 12 months) ]
  6. Aldosterone [ Time Frame: One year (every 12 months) ]
  7. Asymmetric dimethylarginine [ Time Frame: One year (every 12 months) ]
  8. Advanced glycation end product [ Time Frame: One year (every 12 months) ]
  9. (Pro)renin receptor [ Time Frame: One year (every 12 months) ]
  10. Oxidative stress [ Time Frame: One year (every 12 months) ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   16 Years to 75 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • IgA nephropathy confirmed by renal biopsy
  • Hypertension (<= 125/75 mmHg)

Exclusion Criteria:

  • Patients who have been treated with angiotensin type 1 receptor blocker or angiotensin-converting enzyme inhibitor within 4 weeks
  • Severe hypertension (<= 180/110 mmHg) or secondary hypertension
  • Patients with history of allergy or adverse effect for aliskiren
  • Renal dysfunction (estimated Glomerular Filtration Rate < 60 mL/min/1.73m2)
  • Pregnancy
  • Patient treated with cyclosporine
  • Hyperkalemia (serum potassium >= 5.6 mmol/L)
  • Autoimmune disease including systemic lupus erythematosus
  • Patients inadequate for the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01184599

Layout table for location contacts
Contact: Masahito Imanishi +81-6-6929-1221
Contact: Hirofumi Hitomi +81-87-891-2125

Layout table for location information
Kurume University, School of Medicine Recruiting
Fukuoka, Japan, 830-0011
Department of Internal Medicine, Osaka City General Hospital Recruiting
Osaka, Japan, 534-0021
Contact: Masahito Imanishi    +81-6-6929-1221   
Principal Investigator: Masahito Imanishi         
Ohno memorial Hospital Not yet recruiting
Osaka, Japan, 550-0015
Kinki University, Faculty of Medicine Recruiting
Osaka, Japan, 589-8511
Sponsors and Collaborators
Kagawa University
Layout table for investigator information
Principal Investigator: Masahito Imanishi Osaka City General Hospital
Layout table for additonal information
Responsible Party: Hirofumi Hitomi, Kagawa University, Faculty of Medicine Identifier: NCT01184599    
Other Study ID Numbers: OCGH-746
First Posted: August 19, 2010    Key Record Dates
Last Update Posted: June 27, 2011
Last Verified: May 2010
Keywords provided by Kagawa University:
collagen type IV
Transforming Growth Factor beta
prorenin receptor
des-angiotensin I renin substrate
oxidative stress
advanced glycosylation end-product receptor
Additional relevant MeSH terms:
Layout table for MeSH terms
Glomerulonephritis, IGA
Kidney Diseases
Urologic Diseases
Autoimmune Diseases
Immune System Diseases